netbook
desktop
mobile
tablet-landscape
tablet
phone-landscape
phone
Research to Prevent Blindness

Groundbreaking Gene Therapy for Retinal Disease

In March, a 13-year-old boy, Jack Hogan, was the first patient to receive an FDA-approved gene therapy for inherited blindness called Luxturna. The treatment, administered by RPB-supported researchers and physicians at Massachusetts Eye and Ear, is designed to improve visual function in children and adults with inherited retinal disease caused by mutations in the gene RPE65. The lead surgeon is an RPB Career Development Awardee, Jason Comander, MD, PhD, Associate Director of the Inherited Retinal Disorders Service at Mass. Eye and Ear. 

According to Mass. Eye and Ear, Luxturna involves injecting a modified virus into a patient’s eyes to correct a deficiency caused by mutations in the RPE65 gene. These mutations prevent the production or function of a protein needed for proper functioning of the retina, the light-sensitive tissue in the back of the eye that initiates vision. 

Dr. Jason Comander, lead surgeon, and patient Jack Hogan.

 

Photo credit: Massachusetts Eye and Ear

Since receiving his treatment, Hogan has experienced a significant impact on his quality of life. He’s enjoying better vision in low light, such as when playing basketball outside in the evening with friends or going to the movies, and is reading 40 percent smaller print.

"It is truly amazing to see large improvements in Jack’s vision, which would have been impossible without this treatment," said Dr. Comander.  "It is going to make a big difference in his life. These results are representative of just how big a moment this is for gene therapy; it is helping our patients and it is here to stay."

Related News: Feature Story, Gene Therapy, Retina Disorders , Top Story

RPB logo
Watch The Video

Research to Prevent Blindness Celebrates 60th Anniversary

For the past 60 years, RPB has funded groundbreaking research to prevent, treat and cure all conditions that damage or destroy sight.

Read More

 
Letter from NEI

National Eye Institute Recognizes RPB's 60th Anniversary

The NEI congratulates RPB on 60 years of accomplishments in a personal letter from the acting director.

Read More

 
CDA banner art
Watch The Video

In Their Own Words: Why the RPB Career Development Awards Matter

Thank you to our donors for supporting the RPB CDA and launching more than 200 research careers!

Read More

 
Dr. Semenza and colleague work in his lab

Research to Prevent Blindness Grantee Dr. Gregg Semenza Wins Nobel Prize in Medicine

Dr. Semenza is being recognized for his discoveries related to how cells respond to low oxygen levels, which have implications for the treatment of cancer, eye diseases and more.

Read More

 
RPB logo

RPB and Partners Award $1.2 Million In Grants for Novel AMD Research

Four new grantees received the Catalyst Awards for Innovative Research Approaches for AMD.

Read More

 
CDA 30th Anniversary book

The Career Development Award Turns 30: Celebrating a Generation of Support for Early-Career Scientists

CDA founded 30 years ago as one of the few private sources of funding aimed specifically at early-career vision researchers.

Read More

 

Subscribe

Get our email updates filled with the latest news from our researchers about preventing vision loss, treating eye disease and even restoring sight. Unsubscribe at any time. Under our privacy policy, we'll never share your contact information with a third party.